메뉴 건너뛰기




Volumn 66, Issue 11, 2018, Pages 1742-1750

Hepatitis C in Patients with Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes

(13)  Younossi, Zobair M a,b   Stepanova, Maria c   Asselah, Tarik d   Foster, Graham e   Patel, Keyur f   Bräu, Norbert g   Swain, Mark h   Tran, Tram i   Esteban, Rafael j   Colombo, Massimo k   Pianko, Stephen l   Henry, Linda c   Bourliere, Marc m  

d INSERM   (France)

Author keywords

direct acting antivirals; fatigue; healthy liver; vitality; work productivity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR; SOFOSBUVIR PLUS VELPATASVIR PLUS VOXILAPREVIR; ANTIVIRUS AGENT;

EID: 85046722497     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix1106     Document Type: Article
Times cited : (20)

References (57)
  • 2
    • 85013376974 scopus 로고    scopus 로고
    • Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences
    • Younossi ZM, Birerdinc A, Henry L. Hepatitis C infection: a multi-faceted systemic disease with clinical, patient reported and economic consequences. J Hepatol 2016; 65:109-19.
    • (2016) J Hepatol , vol.65 , pp. 109-119
    • Younossi, Z.M.1    Birerdinc, A.2    Henry, L.3
  • 3
    • 84922855628 scopus 로고    scopus 로고
    • Systematic review: Patient-reported outcomes in chronic hepatitis C\-The impact of liver disease and new treatment regimens
    • Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C\-The impact of liver disease and new treatment regimens. Aliment Pharmacol Ther 2015; 41:497-520.
    • (2015) Aliment Pharmacol Ther , vol.41 , pp. 497-520
    • Younossi, Z.1    Henry, L.2
  • 4
    • 84919460742 scopus 로고    scopus 로고
    • The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C
    • Younossi Z, Henry L. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis 2014; 46(Suppl 5):S186-96.
    • (2014) Dig Liver Dis , vol.46 , pp. S186-S196
    • Younossi, Z.1    Henry, L.2
  • 5
  • 6
    • 84964621673 scopus 로고    scopus 로고
    • Extrahepatic manifestations of hepatitis C: A meta-analysis of prevalence, quality of life, and economic burden
    • Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology 2016; 150:1599-608.
    • (2016) Gastroenterology , vol.150 , pp. 1599-1608
    • Younossi, Z.1    Park, H.2    Henry, L.3    Adeyemi, A.4    Stepanova, M.5
  • 7
    • 17144443590 scopus 로고    scopus 로고
    • Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis
    • Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27:209-12.
    • (1998) Hepatology , vol.27 , pp. 209-212
    • Foster, G.R.1    Goldin, R.D.2    Thomas, H.C.3
  • 8
    • 0032769168 scopus 로고    scopus 로고
    • Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response the Interventional Therapy Group
    • Ware JE Jr, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999; 30:550-5.
    • (1999) Hepatology , vol.30 , pp. 550-555
    • Ware, J.E.1    Bayliss, M.S.2    Mannocchia, M.3    Davis, G.L.4
  • 9
    • 1442306694 scopus 로고    scopus 로고
    • Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection
    • Dalgard O, Egeland A, Skaug K, Vilimas K, Steen T. Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. Hepatology 2004; 39:74-80.
    • (2004) Hepatology , vol.39 , pp. 74-80
    • Dalgard, O.1    Egeland, A.2    Skaug, K.3    Vilimas, K.4    Steen, T.5
  • 11
    • 84958964633 scopus 로고    scopus 로고
    • Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection
    • e3
    • Gerber L, Estep M, Stepanova M, Escheik C, Weinstein A, Younossi ZM. Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2016; 14:156-64.e3.
    • (2016) Clin Gastroenterol Hepatol , vol.14 , pp. 156-164
    • Gerber, L.1    Estep, M.2    Stepanova, M.3    Escheik, C.4    Weinstein, A.5    Younossi, Z.M.6
  • 12
    • 84880254060 scopus 로고    scopus 로고
    • Hepatitis C virus infection induces inflammatory cytokines and chemokines mediated by the cross talk between hepatocytes and stellate cells
    • Nishitsuji H, Funami K, Shimizu Y, et al. Hepatitis C virus infection induces inflammatory cytokines and chemokines mediated by the cross talk between hepatocytes and stellate cells. J Virol 2013; 87:8169-78.
    • (2013) J Virol , vol.87 , pp. 8169-8178
    • Nishitsuji, H.1    Funami, K.2    Shimizu, Y.3
  • 13
    • 84887350238 scopus 로고    scopus 로고
    • Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations
    • Zampino R, Marrone A, Restivo L, et al. Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol 2013; 5:528-40.
    • (2013) World J Hepatol , vol.5 , pp. 528-540
    • Zampino, R.1    Marrone, A.2    Restivo, L.3
  • 14
    • 84945436502 scopus 로고    scopus 로고
    • Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels
    • Younossi ZM, Elsheikh E, Stepanova M, et al. Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels. J Viral Hepat 2015; 22:977-82.
    • (2015) J Viral Hepat , vol.22 , pp. 977-982
    • Younossi, Z.M.1    Elsheikh, E.2    Stepanova, M.3
  • 15
    • 85013849411 scopus 로고    scopus 로고
    • The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV)
    • Golabi P, Elsheikh E, Karrar A, et al. The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV). Medicine (Baltimore) 2016; 95:e5066.
    • (2016) Medicine (Baltimore) , vol.95 , pp. e5066
    • Golabi, P.1    Elsheikh, E.2    Karrar, A.3
  • 16
    • 85018671352 scopus 로고    scopus 로고
    • Neurologic manifestations of hepatitis C virus infection
    • Iriana S, Curry MP, Afdhal NH. Neurologic manifestations of hepatitis C virus infection. Clin Liver Dis 2017; 21:535-42.
    • (2017) Clin Liver Dis , vol.21 , pp. 535-542
    • Iriana, S.1    Curry, M.P.2    Afdhal, N.H.3
  • 18
    • 85018700789 scopus 로고    scopus 로고
    • Metabolic manifestations of hepatitis C virus: Diabetes mellitus, dyslipidemia
    • Serfaty L. Metabolic manifestations of hepatitis C virus: diabetes mellitus, dyslipidemia. Clin Liver Dis 2017; 21:475-86.
    • (2017) Clin Liver Dis , vol.21 , pp. 475-486
    • Serfaty, L.1
  • 20
    • 84977648693 scopus 로고    scopus 로고
    • Current treatment of chronic hepatitis C in China: Dilemma and potential problems
    • Han QY, Liu ZW. Current treatment of chronic hepatitis C in China: dilemma and potential problems. World J Gastroenterol 2016; 22:4615-8.
    • (2016) World J Gastroenterol , vol.22 , pp. 4615-4618
    • Han, Q.Y.1    Liu, Z.W.2
  • 21
    • 85012298577 scopus 로고    scopus 로고
    • Management of hepatitis C virus infection in the Asia-Pacific region: An update
    • Lim SG, Aghemo A, Chen PJ, et al. Management of hepatitis C virus infection in the Asia-Pacific region: an update. Lancet Gastroenterol Hepatol 2017; 2:52-62.
    • (2017) Lancet Gastroenterol Hepatol , vol.2 , pp. 52-62
    • Lim, S.G.1    Aghemo, A.2    Chen, P.J.3
  • 22
    • 85001820105 scopus 로고    scopus 로고
    • Pan-genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high-and low-income regions
    • Hézode C. Pan-genotypic treatment regimens for hepatitis C virus: advantages and disadvantages in high-and low-income regions. J Viral Hepat 2017; 24:92-101.
    • (2017) J Viral Hepat , vol.24 , pp. 92-101
    • Hézode, C.1
  • 23
    • 84994814751 scopus 로고    scopus 로고
    • World Health Organization. Accessed 17 November
    • World Health Organization. Combating hepatitis B and C to reach elimination by 2030. Available at: http://apps.who.int/iris/bitstream/10665/206453/1/WHO HIV2016.04eng.pdf. Accessed 17 November 2017.
    • (2017) Combating Hepatitis B and C to Reach Elimination by 2030
  • 24
    • 84961891957 scopus 로고    scopus 로고
    • An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens
    • Younossi ZM, Stepanova M, Henry L, Nader F, Hunt S. An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens. Am J Gastroenterol 2016; 111:808-16.
    • (2016) Am J Gastroenterol , vol.111 , pp. 808-816
    • Younossi, Z.M.1    Stepanova, M.2    Henry, L.3    Nader, F.4    Hunt, S.5
  • 25
    • 84936846849 scopus 로고    scopus 로고
    • The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon-and ribavirin-free regimens: A study of health-related quality of life
    • Younossi ZM, Stepanova M, Nader F, Lam B, Hunt S. The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon-and ribavirin-free regimens: a study of health-related quality of life. Aliment Pharmacol Ther 2015; 42:286-95.
    • (2015) Aliment Pharmacol Ther , vol.42 , pp. 286-295
    • Younossi, Z.M.1    Stepanova, M.2    Nader, F.3    Lam, B.4    Hunt, S.5
  • 26
    • 85011085832 scopus 로고    scopus 로고
    • Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care
    • Younossi ZM, Park H, Dieterich D, Saab S, Ahmed A, Gordon SC. Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: the quality-adjusted cost of care. Medicine (Baltimore) 2016; 95:e5048.
    • (2016) Medicine (Baltimore) , vol.95 , pp. e5048
    • Younossi, Z.M.1    Park, H.2    Dieterich, D.3    Saab, S.4    Ahmed, A.5    Gordon, S.C.6
  • 27
    • 85047196804 scopus 로고    scopus 로고
    • Sofosbuvir-based regimens with task shifting is cost-effective in expanding hepatitis C treatment access in the United States
    • Jayasekera CR, Beckerman R, Smith N, et al. Sofosbuvir-based regimens with task shifting is cost-effective in expanding hepatitis C treatment access in the United States. J Clin Transl Hepatol 2017; 5:16-22.
    • (2017) J Clin Transl Hepatol , vol.5 , pp. 16-22
    • Jayasekera, C.R.1    Beckerman, R.2    Smith, N.3
  • 28
    • 85018785812 scopus 로고    scopus 로고
    • Economic burden of hepatitis C infection
    • Stepanova M, Younossi ZM. Economic burden of hepatitis C infection. Clin Liver Dis 2017; 21:579-94.
    • (2017) Clin Liver Dis , vol.21 , pp. 579-594
    • Stepanova, M.1    Younossi, Z.M.2
  • 29
    • 84959092587 scopus 로고    scopus 로고
    • Disparate access to treatment regimens in chronic hepatitis C patients: Data from the TRIO network
    • Younossi ZM, Bacon BR, Dieterich DT, et al. Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network. J Viral Hepat 2016; 23:447-54.
    • (2016) J Viral Hepat , vol.23 , pp. 447-454
    • Younossi, Z.M.1    Bacon, B.R.2    Dieterich, D.T.3
  • 30
    • 84922770382 scopus 로고    scopus 로고
    • Costeffectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection
    • Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Costeffectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2015; 41:544-63.
    • (2015) Aliment Pharmacol Ther , vol.41 , pp. 544-563
    • Younossi, Z.M.1    Park, H.2    Saab, S.3    Ahmed, A.4    Dieterich, D.5    Gordon, S.C.6
  • 31
    • 84957440472 scopus 로고    scopus 로고
    • Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: An economic model from five European countries
    • Younossi Z, Brown A, Buti M, et al. Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries. J Viral Hepat 2016; 23:217-26.
    • (2016) J Viral Hepat , vol.23 , pp. 217-226
    • Younossi, Z.1    Brown, A.2    Buti, M.3
  • 32
    • 84901439598 scopus 로고    scopus 로고
    • Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens
    • Younossi ZM, Stepanova M, Nader F, et al. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology 2014; 59:2161-9.
    • (2014) Hepatology , vol.59 , pp. 2161-2169
    • Younossi, Z.M.1    Stepanova, M.2    Nader, F.3
  • 33
    • 84936849320 scopus 로고    scopus 로고
    • Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir
    • Younossi ZM, Stepanova M, Afdhal N, et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol 2015; 63:337-45.
    • (2015) J Hepatol , vol.63 , pp. 337-345
    • Younossi, Z.M.1    Stepanova, M.2    Afdhal, N.3
  • 34
    • 84996600359 scopus 로고    scopus 로고
    • Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: An exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial
    • Younossi ZM, Stepanova M, Charlton M, et al. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol 2016; 1:122-32.
    • (2016) Lancet Gastroenterol Hepatol , vol.1 , pp. 122-132
    • Younossi, Z.M.1    Stepanova, M.2    Charlton, M.3
  • 35
    • 84877739274 scopus 로고    scopus 로고
    • Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options
    • POSITRON Study; FUSION Study
    • Jacobson IM, Gordon SC, Kowdley KV, et al.; POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368:1867-77.
    • (2013) N Engl J Med , vol.368 , pp. 1867-1877
    • Jacobson, I.M.1    Gordon, S.C.2    Kowdley, K.V.3
  • 36
    • 84877730954 scopus 로고    scopus 로고
    • Sofosbuvir for previously untreated chronic hepatitis C infection
    • Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-87.
    • (2013) N Engl J Med , vol.368 , pp. 1878-1887
    • Lawitz, E.1    Mangia, A.2    Wyles, D.3
  • 37
    • 84900992889 scopus 로고    scopus 로고
    • Sofosbuvir and ribavirin in HCV genotypes 2 and 3
    • VALENCE Investigators
    • Zeuzem S, Dusheiko GM, Salupere R, et al.; VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370:1993-2001.
    • (2014) N Engl J Med , vol.370 , pp. 1993-2001
    • Zeuzem, S.1    Dusheiko, G.M.2    Salupere, R.3
  • 38
    • 84904570994 scopus 로고    scopus 로고
    • Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection
    • PHOTON-1 Investigators.
    • Sulkowski MS, Naggie S, Lalezari J, et al.; PHOTON-1 Investigators. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312:353-61.
    • (2014) JAMA , vol.312 , pp. 353-361
    • Sulkowski, M.S.1    Naggie, S.2    Lalezari, J.3
  • 39
    • 84900339263 scopus 로고    scopus 로고
    • Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
    • ION-1 Investigators
    • Afdhal N, Zeuzem S, Kwo P, et al.; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889-98.
    • (2014) N Engl J Med , vol.370 , pp. 1889-1898
    • Afdhal, N.1    Zeuzem, S.2    Kwo, P.3
  • 40
    • 84898669547 scopus 로고    scopus 로고
    • Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
    • ION-2 Investigators.
    • Afdhal N, Reddy KR, Nelson DR, et al.; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483-93.
    • (2014) N Engl J Med , vol.370 , pp. 1483-1493
    • Afdhal, N.1    Reddy, K.R.2    Nelson, D.R.3
  • 41
    • 84900326091 scopus 로고    scopus 로고
    • Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
    • ION-3 Investigators.
    • Kowdley KV, Gordon SC, Reddy KR, et al.; ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370:1879-88.
    • (2014) N Engl J Med , vol.370 , pp. 1879-1888
    • Kowdley, K.V.1    Gordon, S.C.2    Reddy, K.R.3
  • 42
    • 84952883325 scopus 로고    scopus 로고
    • Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection
    • ASTRAL-1 Investigators.
    • Feld JJ, Jacobson IM, Hézode C, et al.; ASTRAL-1 Investigators. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015; 373:2599-607.
    • (2015) N Engl J Med , vol.373 , pp. 2599-2607
    • Feld, J.J.1    Jacobson, I.M.2    Hézode, C.3
  • 43
    • 84952909361 scopus 로고    scopus 로고
    • Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection
    • ASTRAL-2 Investigators; ASTRAL-3 Investigators.
    • Foster GR, Afdhal N, Roberts SK, et al.; ASTRAL-2 Investigators; ASTRAL-3 Investigators. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373:2608-17.
    • (2015) N Engl J Med , vol.373 , pp. 2608-2617
    • Foster, G.R.1    Afdhal, N.2    Roberts, S.K.3
  • 44
    • 84952931354 scopus 로고    scopus 로고
    • Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis
    • ASTRAL-4 Investigators.
    • Curry MP, O'Leary JG, Bzowej N, et al.; ASTRAL-4 Investigators. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015; 373:2618-28.
    • (2015) N Engl J Med , vol.373 , pp. 2618-2628
    • Curry, M.P.1    O'Leary, J.G.2    Bzowej, N.3
  • 45
    • 85020200062 scopus 로고    scopus 로고
    • Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection
    • POLARIS-1 and POLARIS-4 Investigators.
    • Bourlière M, Gordon SC, Flamm SL, et al.; POLARIS-1 and POLARIS-4 Investigators. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 2017; 376:2134-46.
    • (2017) N Engl J Med , vol.376 , pp. 2134-2146
    • Bourlière, M.1    Gordon, S.C.2    Flamm, S.L.3
  • 47
    • 1542323315 scopus 로고    scopus 로고
    • The functional assessment of chronic illness therapy (FACIT) measurement system: Validation of version 4 of the core questionnaire
    • Webster K, Odom L, Peterman A, et al. The functional assessment of chronic illness therapy (FACIT) measurement system: validation of version 4 of the core questionnaire. Qual Life Res 1999; 8:604.
    • (1999) Qual Life Res , vol.8 , pp. 604
    • Webster, K.1    Odom, L.2    Peterman, A.3
  • 48
    • 0032864860 scopus 로고    scopus 로고
    • Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease
    • Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999; 45:295-300.
    • (1999) Gut , vol.45 , pp. 295-300
    • Younossi, Z.M.1    Guyatt, G.2    Kiwi, M.3    Boparai, N.4    King, D.5
  • 49
    • 84964662715 scopus 로고    scopus 로고
    • Performance and validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in clinical trials of patients with chronic hepatitis C
    • Younossi ZM, Stepanova M, Henry L. Performance and validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in clinical trials of patients with chronic hepatitis C. Value Health 2016; 19:544-51.
    • (2016) Value Health , vol.19 , pp. 544-551
    • Younossi, Z.M.1    Stepanova, M.2    Henry, L.3
  • 50
    • 0027693577 scopus 로고
    • The validity and reproducibility of a work productivity and activity impairment instrument
    • Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4:353-65.
    • (1993) Pharmacoeconomics , vol.4 , pp. 353-365
    • Reilly, M.C.1    Zbrozek, A.S.2    Dukes, E.M.3
  • 51
    • 34147166155 scopus 로고    scopus 로고
    • Modelling SF-6D health state preference data using a nonparametric Bayesian method
    • Kharroubi SA, Brazier JE, Roberts J, O'Hagan A. Modelling SF-6D health state preference data using a nonparametric Bayesian method. J Health Econ 2007; 26:597-612.
    • (2007) J Health Econ , vol.26 , pp. 597-612
    • Kharroubi, S.A.1    Brazier, J.E.2    Roberts, J.3    O'Hagan, A.4
  • 52
    • 77951083787 scopus 로고    scopus 로고
    • Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)
    • Poynard T, Lebray P, Ingiliz P, et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol 2010; 10:40.
    • (2010) BMC Gastroenterol , vol.10 , pp. 40
    • Poynard, T.1    Lebray, P.2    Ingiliz, P.3
  • 53
    • 33646113599 scopus 로고    scopus 로고
    • Assessment of liver fibrosis progression in patients with chronic hepatitis C and normal alanine aminotransferase values: The role of AST to the platelet ratio index
    • Fabris C, Smirne C, Toniutto P, et al. Assessment of liver fibrosis progression in patients with chronic hepatitis C and normal alanine aminotransferase values: the role of AST to the platelet ratio index. Clin Biochem 2006; 39:339-43.
    • (2006) Clin Biochem , vol.39 , pp. 339-343
    • Fabris, C.1    Smirne, C.2    Toniutto, P.3
  • 54
    • 84929607189 scopus 로고    scopus 로고
    • Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1,-2, and-3 clinical trials
    • Younossi ZM, Stepanova M, Marcellin P, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1,-2, and-3 clinical trials. Hepatology 2015; 61:1798-808.
    • (2015) Hepatology , vol.61 , pp. 1798-1808
    • Younossi, Z.M.1    Stepanova, M.2    Marcellin, P.3
  • 55
    • 16244391099 scopus 로고    scopus 로고
    • Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment
    • Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005; 41:790-800.
    • (2005) Hepatology , vol.41 , pp. 790-800
    • Spiegel, B.M.1    Younossi, Z.M.2    Hays, R.D.3    Revicki, D.4    Robbins, S.5    Kanwal, F.6
  • 56
    • 85047545722 scopus 로고    scopus 로고
    • Changes in serum neurotransmitters (NTs) and patient-reported outcomes (PROs) and neurocognitive performance (NCP) after viral eradication of hepatitis C virus (HCV)-genotype 1 (GT1)
    • de Avila L, Weinstein AA, Golabi P, et al. Changes in serum neurotransmitters (NTs) and patient-reported outcomes (PROs) and neurocognitive performance (NCP) after viral eradication of hepatitis C virus (HCV)-genotype 1 (GT1). Hepatology 2017;66(1 Suppl):600A.
    • (2017) Hepatology , vol.66 , Issue.1 , pp. 600A
    • De Avila, L.1    Weinstein, A.A.2    Golabi, P.3
  • 57
    • 84942021358 scopus 로고    scopus 로고
    • Long-term treatment outcomes of patients infected with hepatitis C virus: A systematic review and meta-analysis of the survival benefit of achieving a sustained virological response
    • Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis 2015; 61:730-40.
    • (2015) Clin Infect Dis , vol.61 , pp. 730-740
    • Simmons, B.1    Saleem, J.2    Heath, K.3    Cooke, G.S.4    Hill, A.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.